Neuronetics to Release Third Quarter Financial Results
MALVERN, Pa. – Neuronetics, Inc. (NASDAQ: STIM), a pioneering company in medical technology, is dedicated to enhancing the quality of life for patients who face neurohealth disorders. The company is known for its innovative NeuroStar Advanced Therapy, which is a leading treatment modality for Transcranial Magnetic Stimulation (TMS). Neuronetics has scheduled the release of its third quarter financial and operating results prior to the market opening on Tuesday, November 4, 2025. This event is crucial for stakeholders eager to understand the company’s performance and future directions.
Details of the Conference Call
The presentation of results will be followed by a live conference call at 8:30 a.m. Eastern Time on the same date. Investors and interested parties can access the conference through a webcast, allowing a broad audience to stay updated. For those who prefer joining via telephone, prior registration for the call is recommended to streamline the experience. Participants are encouraged to dial in approximately 10 minutes ahead of the call to ensure timely participation.
About Neuronetics and Its Mission
Neuronetics embraces the philosophy that mental health is equally vital as physical well-being. As a leader in neuroscience, the company focuses on providing effective in-office treatments that yield remarkable results. The flagship NeuroStar Advanced Therapy represents a non-drug, non-invasive option that significantly enhances the quality of life for individuals suffering from neurohealth conditions when traditional medications fall short.
Expanding Treatment Options
In addition to the commercialization of the NeuroStar Advanced Therapy System, Neuronetics operates the Greenbrook TMS Inc. treatment centers across various regions, actively delivering NeuroStar Advanced Therapy to manage Major Depressive Disorder (MDD) and other mental health challenges. This system stands out as the leading TMS treatment for MDD in adults, with an impressive record of over 7.6 million treatments administered. It is supported by the most extensive clinical data available for TMS therapies, which includes the largest depression outcomes registry worldwide.
Innovative Solutions for Depression Treatment
The treatment centers not only offer NeuroStar Advanced Therapy but also provide therapies such as SPRAVATO® (esketamine) Nasal Spray. This prescription medication is designed for treatment-resistant depression as both a standalone treatment and in combination with oral antidepressants. Furthermore, SPRAVATO is indicated for adults presenting depressive symptoms accompanied by acute suicidal ideation within the context of MDD, further addressing critical patient needs.
Regulatory Approval and Safety Considerations
The NeuroStar Advanced Therapy System has received clearance from the U.S. Food and Drug Administration. It is designated for adults facing MDD and is also recognized as an adjunct therapy for individuals suffering from obsessive-compulsive disorder (OCD). Additionally, it is effective in alleviating anxiety symptoms associated with depression and is approved as an essential treatment option for adolescents aged 15 to 21 facing MDD.
Contact Information for Interested Parties
Individuals with inquiries or requiring more information are encouraged to reach out to the dedicated investor and media contacts. Mike Vallie and Mark Klausner from ICR Healthcare are available for investor relations at 443-213-0499 or via email at ir@neuronetics.com. For media-related inquiries, EvolveMKD can be reached at 646-517-4220 or through email at NeuroStar@evolvemkd.com.
Frequently Asked Questions
What is the purpose of Neuronetics' upcoming conference call?
The goal of the conference call is to discuss the company's financial and operating results for the third quarter and provide insights into future plans.
When is the conference call scheduled?
The conference call is set for 8:30 a.m. Eastern Time on the morning of November 4, 2025.
How can I listen to the conference call?
Participants can listen via a live webcast or telephone by registering for the call in advance.
What innovative treatments does Neuronetics offer?
Neuronetics provides NeuroStar Advanced Therapy and also offers SPRAVATO for treatment-resistant depression.
Who can I contact for more information about Neuronetics?
Contact Mike Vallie or Mark Klausner at ICR Healthcare for investor inquiries, or reach out to EvolveMKD for media inquiries.
